key: cord-0073280-qyj9exli
authors: Paitazoglou, Christina; Bergmann, Martin W.; Tiemann, Katharina; Wiese, Andrea; Schäfer, Ulrich; Schwarz, Arne; Eitel, Ingo; Montenbruck, Moritz
title: Atrial Giant Cell Myocarditis as a Cause of Heart Failure: Diagnostic Pathway and Successful Treatment
date: 2022-01-05
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2021.11.007
sha: e61ecdbd4f7f5678256d7993c6a0f60c9427856b
doc_id: 73280
cord_uid: qyj9exli

We present a patient with acute heart failure and new onset atrial fibrillation secondary to giant cell myocarditis with lone atrial involvement. The diagnosis was managed with cardiac magnetic resonance and confirmed by interventionally guided biopsy. In the future, diagnosis could be managed noninvasively for this rare entity as the gold standard. (Level of Difficulty: Advanced.)

tions. Additionally, she reported a weight loss of 4 kg (weight, 50 kg; body mass index, 17.5 kg/m 2 ), night sweats, and low appetite for 4 weeks. She was afebrile, with a blood pressure of 120/70 mm Hg and a heart rate of 126 beats/min. Electrocardiography showed newly diagnosed persistent atrial fibrillation (AF) (CHA 2 DS 2 -VASc-score of 3).

There was no cardiac or other relevant medical history, no recent infections or COVID-19. The patient had undergone regular cancer screening in the past.

Possible differential diagnoses included acute heart decompensation resulting from new onset AF or myocarditis or a malignant disease.

To diagnose precisely in future this rare entity of atrial GCM and to rule out ventricular inflammation or storage diseases noninvasively by imaging evaluation with CMR as the gold standard. To pay special attention to atrial and septal wall thickening as signs of atrial inflammation for clinicians conducting the imaging. Additionally, CMR showed normal ventricular function.

Heart failure (HF) medication with an oral angiotensin receptor antagonist (candesartan, 8 mg/d) and a beta-blocker (metoprolol, 95 mg/d), as well as oral anticoagulation with a direct oral anticoagulant agent (apixaban, 10 mg/d) was initiated. AF heart rate control was achieved by digitoxin (0.07 mg/d).

The case was discussed within the institutional heart team, and we proposed performing an inter- Atrial cardiomyopathy may be a cause of recurrent AF. Atrial GCM was first described in 1964 in a case report. 4 The pathophysiology of GCM is not well understood beyond its recognition as an autoimmune disorder attributable to T-lymphocyte-mediated myocardial inflammation. 1 In published reports, some atrial GCM cases have been associated with autoimmune disorders 4, 5 ; however, another series of cases indicated that atrial GCM was a distinct entity. 

Treatment with prednisolone monotherapy in our patient led to full recovery and conversion to sinus rhythm at 3-month follow-up. However, the role of immunosuppressive treatment remains unknown for this rare entity, and additional studies will therefore be required before conclusions can be made regarding the long-term efficacy of this approach. 

GCM affecting only the atria differs from the ventricular GCM entity. We show a case of atrial GCM leading to AF and HF in a patient whose accurate diagnosis was managed primarily noninvasively by CMR, followed by atrial septal and ventricular biopsies and selected treatment with prednisolone monotherapy, leading to full recovery.

The authors have reported that they have no relationships relevant to the contents of this paper to disclose. 

Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression

Atrial giant cell myocarditis: a distinctive clinicopathologic entity

Left atrial giant cell myocarditis presenting as a tumor: First-in-man case report

Two unusual cases of giant cell myocarditis associated with mitral stenosis and with Wegener's syndrome

Mitral stenosis together with a giant cell myocarditis limited to the left atrium

Atrial giant cell myocarditis after atrial fibrillation ablation

KEY WORDS atrial giant cell myocarditis, cardiac magnetic resonance, heart failure, magnetic resonance imaging APPENDIX For supplemental videos, please see the online version of this paper